NIFTY 50▲22,402.40
34.40 (0.15%)
SENSEX▲73,852.94
114.49 (0.16%)
NIFTY BANK▲48,189.00
218.55 (0.46%)
TATA MOTORS▲991.65
4.90 (0.50%)
INDIAN RAILWAY FINANCE CORP▲149.00
1.25 (0.85%)
SUZLON ENERGY▼41.80
-0.05 (-0.12%)
TATA POWER▼428.30
-1.35 (-0.31%)
TATA STEEL▲165.55
4.40 (2.73%)
YES BANK▼25.45
-0.20 (-0.78%)
INDIAN RENEWABLE ENERGY▼166.60
-1.35 (-0.80%)
RELIANCE INDUSTRIES▼2,900.35
-18.30 (-0.63%)
RELIANCE POWER▼27.60
-0.40 (-1.43%)
VODAFONE IDEA▼13.10
-1.30 (-9.03%)
HDFC BANK▲1,511.70
4.10 (0.27%)
JIO FIN SERVICES LTD▼381.85
-6.10 (-1.57%)
RAIL VIKAS NIGAM▲284.25
6.90 (2.49%)
ADANI POWER▼596.50
-5.95 (-0.99%)
ZOMATO▼184.40
-3.05 (-1.63%)
NHPC▲90.25
0.50 (0.56%)
STATE BANK OF INDIA▲773.10
0.10 (0.01%)
INDIAN RAILWAY TOURISM CORP▲1,025.35
9.05 (0.89%)
INDIAN OIL CORP▲168.75
0.65 (0.39%)
MRF▼1,28,524.45
-702.25 (-0.54%)
ITC▼428.90
-0.30 (-0.07%)
ADANI GREEN ENERGY▼1,808.30
-8.10 (-0.45%)
JAIPRAKASH POWER VENTURES▼18.05
-0.20 (-1.10%)
ADANI ENTERPRISES▼3,043.55
-21.55 (-0.70%)
ADANI PORT & SEZ▼1,320.50
-1.60 (-0.12%)
80% Hold
GlaxoSmithKline Pharma Share Price
GLAXO
₹2,077.25+₹130.50 (6.70%) Past YearLast updated on 24 Apr, 2024 | 03:58 PM IST
₹1,954.25₹2,087.00
LH
What’s in news?
Company overview
About
Market cap
| Open₹1,956.50 | Close₹1,946.75 |
Circuit range₹2,336.10 - ₹1,557.40 | Day range₹1,954.25 - ₹2,087.00 | Year range₹1,227.00 - ₹2,524.00 |
Volume2,78,853 | Avg. traded₹2,034.44 | Revenue (12m)₹3,311 Cr |
GlaxoSmithKline PharmaGlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Read more
GlaxoSmithKline Pharma Key indicators
52 week high₹2,524.00 | 52 week low₹1,227.00 | P/E ratio62.34 |
P/B ratio20.76 | ROE27.29% | ROCE37.66% |
Dividend yield1.65% | Debt/Equity ratio | EPS35.7 |
Learn more
Featured in
Investment checklist: (3/6)
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Hold
Analyst ratings:
Hold20%
Hold
80%
Sell
0%
This analysis is based on the reviews of 5 experts in the last 7 days
Fundamentals
Financial ratios
Operating profit margin25.5% | Net profit margin17.12% |
ROE27.29% | ROA15.7% |
ROCE37.66% |
Learn more
Revenue statement
All values are in ₹ Crores (Cr)No data available at the moment
Cash flow
All values are in ₹ Crores (Cr)No data available at the moment
Balance sheet
All values are in ₹ Crores (Cr)No data available at the moment
GlaxoSmithKline Pharma Share Price history
Day | Open | Close | Day’s change |
---|---|---|---|
Tue, Apr 23 2024 | ₹1,950.00 | ₹1,946.75 | -0.17% |
Mon, Apr 22 2024 | ₹1,872.00 | ₹1,950.05 | |
Fri, Apr 19 2024 | ₹1,878.15 | ₹1,871.20 | -0.37% |
Thu, Apr 18 2024 | ₹1,922.95 | ₹1,888.15 | -1.84% |
Tue, Apr 16 2024 | ₹1,902.75 | ₹1,898.80 | -0.21% |
Mon, Apr 15 2024 | ₹1,876.10 | ₹1,902.20 | |
Fri, Apr 12 2024 | ₹1,890.05 | ₹1,881.40 | -0.46% |
Wed, Apr 10 2024 | ₹1,913.25 | ₹1,896.45 | -0.89% |
Events
Corporate actions
Dividend • ₹32/share
Ex date 30 Jun 2023
Dividend • ₹60/share
Ex date 07 Jul 2022
Dividend • ₹30/share
Ex date 07 Jul 2022
Learn more